batoprotafib   Click here for help

GtoPdb Ligand ID: 12068

Synonyms: compound 1 [PMID: 32910655] | TNO-155 | TNO155
PDB Ligand
Compound class: Synthetic organic
Comment: TNO155 is an oral, allosteric inhibitor of SHP2 (a nonreceptor protein tyrosine phosphatase that's encoded by the PTPN11 gene) [1]. SHP2 is an oncoprotein in its own right, but its inhibition is also being exploited to combat tumours that are driven by hyperactivation in the RAS-RAF-ERK signalling pathway.
We matched TNO155's chemical structure to the INN 'batoprotafib' which was published in the WHO's proposed INN list 127 on 21 July 2022.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

batoprotafib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 3
Topological polar surface area 154.5
Molecular weight 421.15
XLogP 2.08
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES N[C@@H]1[C@H](C)OCC21CCN(CC2)c1cnc(c(n1)N)Sc1ccnc(c1Cl)N
Isomeric SMILES Nc1nc(N2CCC3(CO[C@@H](C)[C@H]3N)CC2)cnc1Sc1c(Cl)c(N)ncc1
InChI InChI=1S/C18H24ClN7OS/c1-10-14(20)18(9-27-10)3-6-26(7-4-18)12-8-24-17(16(22)25-12)28-11-2-5-23-15(21)13(11)19/h2,5,8,10,14H,3-4,6-7,9,20H2,1H3,(H2,21,23)(H2,22,25)/t10-,14+/m0/s1
InChI Key UCJZOKGUEJUNIO-IINYFYTJSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
TNO155 has been progressed to clinical evaluations in a range of advanced solid tumours, including those that are KRASG12C positive.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04330664 Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) Phase 1/Phase 2 Interventional Mirati Therapeutics Inc.
NCT04699188 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Phase 1/Phase 2 Interventional Novartis
NCT04292119 Lorlatinib Combinations in Lung Cancer Phase 1/Phase 2 Interventional Massachusetts General Hospital